Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update -- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc® for permanent non- surgical birth control continues -- ATLANTA, May 9, 2024 -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic produc ...

-- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc® for permanent non-surgical birth control continues -- ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2024 and provides a corporate up ...

ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces the expansion of its commercial management team, marking a significant milestone in the company's mission to advance women's health worldwide. With the addition of new team members to its commercial team in key strategic geographic ...

Femasys Inc. (FEMY) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stoc ...

ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces its CEO and Founder Kathy Lee-Sepsick has met with several members of Congress to discuss the current women's healthcare landscape. Further, Lee-Sepsick is raising awareness of Femasys and the status of its reproductive products ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40492 Femasys Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 11-3713499 (State or other jurisdiction of incorp ...

Exhibit 99.1 Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update -- Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025 -- ATLANTA, March 28, 2024 -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, a ...

ATLANTA, March 21, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing the significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, invites investors to join management in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women. Those interested in attending the event, which will be held vir ...

FemaSeed产品特点 - FemaSeed是一种定位方向性人工受孕产品，成功率高达24%[1] - FemaSeed在严重男性因素不孕症患者中的成功率是传统宫腔内受精(IUI)的两倍以上[1] - 大多数成功怀孕的患者只需要一次FemaSeed程序[1] - FemaSeed的安全性得到验证，没有新的安全问题[1] Femasys公司发展 - Femasys的首席执行官Kathy Lee-Sepsick表示，FemaSeed在治疗不孕症方面取得了显著进展，支持其作为首选治疗选择[2] - Femasys的目标是为医疗专业人员提供安全、可访问和经济实惠的替代方案，以扩大其服务范围[3] FDA批准 - FemaSeed已获得FDA批准，为女性及其医生提供了更安全、更经济的人工受孕选择[4]

Femasys公司介绍 - Femasys公司将与Jones Trading分析师Catherine Novack进行线上讨论，探讨女性不孕症治疗领域的现状和FemaSeed®产品[1] - Femasys的CEO Kathy Lee-Sepsick和首席医疗官James Liu将重点关注不孕症服务市场的当前治疗选择，包括FemaSeed®产品[2] - Femasys公司创始人Kathy Lee-Sepsick在医疗技术行业拥有近30年的经验，而首席医疗官James Liu曾在多家医疗机构担任重要职务[3] - FemaSeed®是一种创新的不孕症治疗方法，旨在将精子输送到输卵管，提高自然受孕机会，比IVF等辅助生殖程序更少侵入性和更经济[4]